Anebulo Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANEB) $2.36 -0.01 (-0.42%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$2.11▼$2.4450-Day Range$1.71▼$3.2752-Week Range$1.62▼$4.05Volume5,750 shsAverage Volume9,514 shsMarket Capitalization$60.49 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Anebulo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside182.5% Upside$6.67 Price TargetShort InterestHealthy0.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.29Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.46) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector379th out of 952 stocksPharmaceutical Preparations Industry169th out of 434 stocks 3.5 Analyst's Opinion Consensus RatingAnebulo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.67, Anebulo Pharmaceuticals has a forecasted upside of 182.5% from its current price of $2.36.Amount of Analyst CoverageAnebulo Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.11% of the float of Anebulo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAnebulo Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anebulo Pharmaceuticals has recently decreased by 56.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnebulo Pharmaceuticals does not currently pay a dividend.Dividend GrowthAnebulo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANEB. Previous Next 2.9 News and Social Media Coverage News SentimentAnebulo Pharmaceuticals has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Anebulo Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Anebulo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders85.90% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.44% of the stock of Anebulo Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anebulo Pharmaceuticals are expected to decrease in the coming year, from ($0.46) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anebulo Pharmaceuticals is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anebulo Pharmaceuticals is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnebulo Pharmaceuticals has a P/B Ratio of 5.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Read More ANEB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANEB Stock News HeadlinesNovember 29, 2023 | americanbankingnews.comShort Interest in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Declines By 56.1%November 21, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Brainsway (BWAY)December 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 17, 2023 | markets.businessinsider.comBuy Recommendation for Anebulo Pharmaceuticals: Promising Financial Outlook and Potential Breakthrough in Acute Cannabis Intoxication TreatmentNovember 15, 2023 | msn.comAnebulo Pharmaceuticals GAAP EPS of -$0.10 beats by $0.02November 14, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNovember 6, 2023 | finance.yahoo.comHere's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn SituationOctober 19, 2023 | msn.comAre Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?December 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 11, 2023 | benzinga.comDirector at Anebulo Pharmaceuticals Acquires Company Stock Options Worth 26,097 SharesOctober 6, 2023 | marketwatch.comAnebulo Pharmaceuticals Names Richie Cunningham as CEOOctober 6, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsOctober 6, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Announces New CEOSeptember 25, 2023 | msn.comHC Wainwright & Co. Reiterates Anebulo Pharmaceuticals (ANEB) Buy RecommendationSeptember 25, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Anebulo Pharmaceuticals (ANEB)September 23, 2023 | nasdaq.comMaxim Group Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 22, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Aurinia Pharmaceuticals (AUPH) and Aquestive Therapeutics (AQST)September 20, 2023 | finance.yahoo.comAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesSeptember 18, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Anebulo Pharmaceuticals (ANEB) with Buy RecommendationSeptember 18, 2023 | markets.businessinsider.comSubstance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst SaysSeptember 18, 2023 | markets.businessinsider.comAnebulo Pharmaceuticals (ANEB) Has a New Rating from H.C. WainwrightAugust 30, 2023 | finance.yahoo.comAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesAugust 22, 2023 | finance.yahoo.comAnebulo (ANEB) Gains on Positive FDA Response for ANEB-001August 21, 2023 | markets.businessinsider.comAnebulo Pharma: FDA Provides Favorable Input On Studies To Support ANEB-001 ApprovalAugust 21, 2023 | finance.yahoo.comAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionMay 30, 2023 | finance.yahoo.comWe Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Needs To Drive Business Growth CarefullyMay 19, 2023 | finance.yahoo.comDown -26.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Anebulo Pharmaceuticals, Inc. (ANEB)See More Headlines Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/20/2023Today12/04/2023Next Earnings (Estimated)2/09/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANEB CUSIPN/A CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$6.67 High Stock Price Target$8.00 Low Stock Price Target$6.00 Potential Upside/Downside+182.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.93% Return on Assets-89.18% Debt Debt-to-Equity RatioN/A Current Ratio12.62 Quick Ratio12.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book5.76Miscellaneous Outstanding Shares25,630,000Free Float3,614,000Market Cap$60.49 million OptionableNot Optionable Beta-1.14 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Joseph F. Lawler M.D. (Age 51)Ph.D., Founder & Chairman Comp: $11kDr. Kenneth C. Cundy Ph.D. (Age 64)Chief Scientific Officer Comp: $425.15kMr. Richard Anthony Cunningham (Age 52)CEO & Director Mr. Daniel V. George (Age 53)Principal Accounting Officer, Acting CFO & Secretary Mr. Scott L. AndersonHead of Investor Relations & Public AffairsKey CompetitorsCoya TherapeuticsNASDAQ:COYASyros PharmaceuticalsNASDAQ:SYRSVYNE TherapeuticsNASDAQ:VYNEADC TherapeuticsNYSE:ADCTCervoMedNASDAQ:CRVOView All CompetitorsInstitutional OwnershipTower Research Capital LLC TRC Bought 14,750 shares on 11/14/2023Ownership: 0.081%View All Institutional Transactions ANEB Stock Analysis - Frequently Asked Questions Should I buy or sell Anebulo Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANEB shares. View ANEB analyst ratings or view top-rated stocks. What is Anebulo Pharmaceuticals' stock price target for 2024? 3 brokerages have issued 12 month price targets for Anebulo Pharmaceuticals' shares. Their ANEB share price targets range from $6.00 to $8.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 182.5% from the stock's current price. View analysts price targets for ANEB or view top-rated stocks among Wall Street analysts. How have ANEB shares performed in 2023? Anebulo Pharmaceuticals' stock was trading at $2.4237 at the beginning of the year. Since then, ANEB stock has decreased by 2.6% and is now trading at $2.36. View the best growth stocks for 2023 here. Are investors shorting Anebulo Pharmaceuticals? Anebulo Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 2,500 shares, a decline of 56.1% from the October 31st total of 5,700 shares. Based on an average trading volume of 18,700 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short. View Anebulo Pharmaceuticals' Short Interest. When is Anebulo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 9th 2024. View our ANEB earnings forecast. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) released its quarterly earnings results on Wednesday, September, 20th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10). When did Anebulo Pharmaceuticals IPO? (ANEB) raised $21 million in an IPO on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO. Who are Anebulo Pharmaceuticals' major shareholders? Anebulo Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Tower Research Capital LLC TRC (0.08%). View institutional ownership trends. How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ANEB) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.